http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008029031-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f08a7dd141d8b0e7453e2ac67360eeda |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6842 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6851 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate | 2007-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3a933106b7f16a2f191e72605337dd4 |
publicationDate | 2008-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2008029031-A2 |
titleOfInvention | Pharmacodiagnostic test targeting oncology |
abstract | A first objective of the present invention is to demonstrate a method for the detection and prognosis of cancer and of its metastatic potential. Preferably, the cancer is selected from breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, a sarcoma and a leukaemia, without being limited thereto. One aspect of the present invention consists of the use of the LIV21 complex as a prognostic indicator for cancer and in the therapeutic monitoring thereof. The LIV21 complex is defined in terms of the extract of proteins and peptides studied by Maldi and ESI MS/MS or Maldi Tof/Tof mass spectrometry. Said extract was obtained by attachment of the LIV21 complex to one of these LIV21 polyclonal antibodies. The LIV21 complex is also defined in terms of its overall mass spectrometry profile (Figure 5) and the number and the molecular weight of the bands of protein extracts obtained as a function of the temperature to which the sample is subjected and the migration conditions described. Another aspect is the use of biochips for the pharmacodiagnosis of oncological pathologies and of neurodegeneration. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10718029-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2950076-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101963617-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101963617-B |
priorityDate | 2006-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.